Clinical trial · no report yet · Phase 1/Phase 2
NCT06385925
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- NCT06385925 ↗
- Recruiting
- Tyligand Pharmaceuticals (Suzhou) Limited
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Phase 1/2 Study of TSN1611 in Subjects With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Malignant Neoplasm
- Interventions
- TSN1611; TSN1611; TSN1611; TSN1611
- Arms
- Phase 1: Dose-finding/evaluation of TSN1611 monotherapy · Experimental
- Phase 2: Dose expansion of TSN1611 monotherapy · Experimental
- Dose of Phase 1b/2 part of TSN1611 combination therapy-Cohort A · Experimental
- Dose of Phase 1b/2 part of TSN1611 combination therapy-Cohort B · Experimental
- Dose of Phase 1b/2 part of TSN1611 combination therapy-Cohort C · Experimental
- Enrollment
- 440 (estimated)
- Primary outcomes
- Dose limiting toxicities (DLTs) in phase 1 part
- Objective response rate (ORR) in phase 2 part
- Sponsor
- Tyligand Pharmaceuticals (Suzhou) Limited
- Start
- Apr 29, 2024
- Primary completion
- Oct 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06385925 · updated Apr 24, 2026